Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $15.1K | $487K | — | — | — |
| Revenue growth | — | — | 3130.4% | — | — | — |
| Gross profit | — | -$2.21K | — | — | — | — |
| Gross margin | — | -14.7% | — | — | — | — |
| Operating income | — | -$4.51M | -$12.6M | -$16.0M | -$14.2M | -$20.9M |
| Operating margin | — | -29925.7% | -2587.3% | — | — | — |
| Net income | — | -$2.17M | -$13.9M | -$16.0M | -$13.9M | -$20.4M |
| Net margin | — | -14430.5% | -2864.3% | — | — | — |
| EPS (diluted) | — | -$0.21 | -$1.76 | -$0.42 | -$12.69 | -$2.91 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | — | -$3.17M | -$14.6M | -$12.8M | -$13.9M | -$15.2M |
| Capital expenditures | — | $21.5K | $107K | $34.3K | — | — |
| Free cash flow | — | -$3.20M | -$14.7M | -$12.8M | — | — |
| Share buybacks | — | — | — | $3.73M | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $244K | $53.0M | $33.1M | $16.3M | $6.92M | $55.2M |
| Total assets | $248K | $53.3M | $45.2M | $26.1M | $16.1M | $60.2M |
| Total liabilities | $6.60K | $1.90M | $2.68M | $2.72M | $1.28M | $5.02M |
| Shareholders' equity | $241K | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M |
| Retained earnings | -$41.0K | -$2.21M | -$19.4M | -$35.3M | -$49.6M | -$70.0M |
| Shares (wtd avg diluted) | 7.47M | 10.4M | 1.26M | 1.23M | 1.10M | 7.03M |
Every figure is extracted from Pasithea Therapeutics Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.